MyOme, a Menlo Park, CA-based clinical whole genome platform analysis company, raised $23m in Series B financing.
The round, which brought the total raised to over $36M, was led by Healthcare Venture Partners.
The company intends to use the funds to begin commercialization of its clinical whole genome analysis platform technology and clinical reports to health systems.
Led by Premal Shah, PhD, CEO, and Matthew Rabinowitz, PhD, co-founder and chairman, MyOme is a clinical whole genome analysis platform company allowing families to understand their risk for inherited diseases. It is certified under the Clinical Laboratory Improvement Amendments (CLIA).